Aimovig® receives EMA license for the prevention of migraine

Written by Sharon Salt, Editor

Novartis (Frimley, UK) has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the USA and Australia. The latest information on migraine reveals that over 610,000 individuals in the UK are estimated to experience chronic migraines (15 or more headache days per month, of which eight involve migraine symptoms), with the 2010 Equality Act classifying migraine as a disability should...

To view this content, please register now for access

It's completely free